Dr. Mark S. Sulkowski

powered by
COS Expertise®
Johns Hopkins University
School of Medicine
Medicine
Infectious Disease
Associate ProfessorAppointed: 1998
Professional Headshot of Mark S. Sulkowski

Mailing Address

600 North Wolfe Street
1830 Building
Room 445
Baltimore, Maryland 21287-0003
United States

Contact Information

Phone: (410) 614-6089
Fax: (410) 614-5138
msulkowski@jhmi.edu

Qualifications

Fellow, Johns Hopkins University, Infectious Diseases, 1998.
Intern/Resident, Duke University, Internal Medicine, 1995.
M.D., Temple University, Medicine, 1992.
B.S., Lehigh University, Biology, 1988.

Other Expertise

1. Clinical trials - treatment of hepatitis C virus infection
2. Clinical management of hepatitis C and B in persons with and without HIV coinfection

Keywords

COS Keywords:

Hepatitis, HIV, Infectious Diseases Or Agents.

Additional Terms:

Hepatitis B Virus Infection (HBV), Hepatitis C Virus Infection (HCV), Hepatitis C/HIV Coinfection.

Memberships

Alpha Omega Alpha
American Association for the Study of Liver Diseases
European Association for the Study of the Liver (EASL)
Infectious Diseases Society of America
Phi Beta Kappa

Publications

  • Sulkowski MS, Dieterich DT, Bini EJ, Brau N, Alvarez D, Dejesus E, Leitz GJ, for the HIV/HCV Coinfection Study Group (Aug 2005) Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial, Journal of Acquired Immune Deficiency Syndromes (1999), 39 (4), 504-6
  • Sulkowski MS, Dieterich DT, Bini EJ, Brau N, Alvarez D, Dejesus E, Leitz GJ, for the HIV/HCV Coinfection Study Group (Aug 2005) Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial, Journal of Acquired Immune Deficiency Syndromes (1999), 39 (4), 504-6
  • Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL (Mar 2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus, Aids (london, England), 19 (6), 585-92
  • Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE, AIDS Clinical Trials Group A5088 Protocol Team (Mar 2005) Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection, The Journal of Infectious Diseases, 191 (5), 686-93
  • Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S (Mar 2005) Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy, Clinical Pharmacology and Therapeutics, 77 (3), 214-24
  • Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL (Mar 2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus, Aids (london, England), 19 (6), 585-92
  • Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE, Moore RD, Sulkowski MS (Jan 2005) The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection, Hepatology (baltimore, Md.), 41 (1), 123-31
  • Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE, Moore RD, Sulkowski MS (Jan 2005) The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection, Hepatology (baltimore, Md.), 41 (1), 123-31
  • Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, PROACTIVE Study Group (Dec 2004) Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy, Hepatology (baltimore, Md.), 40 (6), 1450-8
  • Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH, PROACTIVE Study Group (Dec 2004) Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy, Hepatology (baltimore, Md.), 40 (6), 1450-8
  • Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD (Nov 2004) Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir, Aids (london, England), 18 (17), 2277-84
  • Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ, Proactive Study Group (May 2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study, Gastroenterology, 126 (5), 1302-11
  • Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ, Proactive Study Group (May 2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study, Gastroenterology, 126 (5), 1302-11
  • Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R (May 2004) Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection, Journal of Viral Hepatitis, 11 (3), 243-50
  • Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ, Proactive Study Group (May 2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study, Gastroenterology, 126 (5), 1302-11
  • Sulkowski MS (Apr 2004) Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person, Hepatology (baltimore, Md.), 39 (4), 906-8
  • Sulkowski MS (Apr 2004) Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person, Hepatology (baltimore, Md.), 39 (4), 906-8
  • Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A, Rockstroh J (Jan 2004) Care of patients with hepatitis C and HIV co-infection, Aids (london, England), 18 (1), 1-12
  • Sterling RK, Sulkowski MS (2004) Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection, Seminars in Liver Disease, 24 Suppl 2, 61-8
  • Emens LA, Sulkowski MS (Dec 2002) Regression of splenic lymphoma after treatment of hepatitis C virus infection, The New England Journal of Medicine, 347 (26), 2168-70; author repl
  • Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB (Nov 2002) Role of liver biopsy in management of chronic hepatitis C: a systematic review, Hepatology (baltimore, Md.), 36 (5 Suppl 1), S161-72
  • Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA (Nov 2002) Treatment of chronic hepatitis C: a systematic review, Hepatology (baltimore, Md.), 36 (5 Suppl 1), S135-44
  • Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL (Jul 2002) Hepatitis C and progression of HIV disease, Jama : the Journal of the American Medical Association, 288 (2), 199-206
  • Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL (Jul 2002) Hepatitis C and progression of HIV disease, Jama : the Journal of the American Medical Association, 288 (2), 199-206
  • Gebo KA, Jenckes MW, Chander G, Torbenson MS, Ghanem KG, Herlong HF, Sulkowski MS, El-Kamary SS, Harris KA, Guedelhoefer OC, Bass EB (Jun 2002) Management of chronic hepatitis C, Evidence Report/technology Assessment (summary) (60), 1-7
  • Sulkowski MS, Ray SC, Thomas DL (May 2002) Needlestick transmission of hepatitis C, Jama : the Journal of the American Medical Association, 287 (18), 2406-13
  • Sulkowski MS, Ray SC, Thomas DL (May 2002) Needlestick transmission of hepatitis C, Jama : the Journal of the American Medical Association, 287 (18), 2406-13
  • Sulkowski M, Reindollar R, Thomas DL, Brinkley-Laughton S, Hudson M, Yu J (2002) Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study, Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 16 (2), 105-9
  • Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (Jan 2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections, Hepatology (baltimore, Md.), 35 (1), 182-9
  • Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL, Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States, Hepatology (baltimore, Md.), 33(6), 1554, Jun 2001
  • Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, Goodman SN (Jan 2001) Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials, Jama : the Journal of the American Medical Association, 285 (2), 193-9
  • Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (Oct 2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States, Annals of Internal Medicine, 133 (8), 592-9
  • Sulkowski MS, Mast EE, Seeff LB, Thomas DL (Apr 2000) Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 30 Suppl 1, S77-84
  • Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (Jan 2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection, Jama : the Journal of the American Medical Association, 283 (1), 74-80

Profile Details

Last Updated: 1/3/2008

COS Expertise ID #1227632
Reference this profile directly: http://myprofile.cos.com/msulkowski